U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C9H8N3O2S2.Zn
Molecular Weight 574.026
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFATHIAZOLE ZINC

SMILES

[Zn++].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=NC=CS2.NC3=CC=C(C=C3)S(=O)(=O)[N-]C4=NC=CS4

InChI

InChIKey=BYDMFZFWWZCIFA-UHFFFAOYSA-N
InChI=1S/2C9H8N3O2S2.Zn/c2*10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9;/h2*1-6H,10H2;/q2*-1;+2

HIDE SMILES / InChI
Molecular Formula C9H9N3O2S2
Molecular Weight 255.317
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.mims.com/india/drug/info/sulfathiazole?type=full&mtype=generic#Indications

Sulfathiazole is a short-acting sulfonamide with properties similar to those of sulfamethoxazole. It is now rarely used systemically due to its toxicity. Sulfathiazole is used with other sulfonamides, usually sulfabenzamide and sulfacetamide, in preparations for the topical treatment of vaginal infections and is also used with other drugs in the treatment of skin infections. Sulfathiazole sodium has been applied topically with other drugs in the treatment of eye infections. Sulfathiazole interferes with nucleic acid synthesis in microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid.It has properties similar to sulfamethoxazole.

Originator

Fosbinder, R.J.|Walter, L.A.
9
Curator's Comment: Introduced as Tiazol by C. and C. https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA3112&lpg=PA3112&dq=sulfathiazole retrieved from Pharmaceutical Manufacturing Encyclopedia, 3rd Edition William Andrew Publishing, p.3112

Approval Year

1940
58
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
Sulfathiazole

Approved Use

Vaginal infections
Doses

Doses

DosePopulationAdverse events​
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Disc. AE: Dermatitis, Nausea and vomiting...
Other AEs: Nitrogen retention, Hematuria...
AEs leading to
discontinuation/dose reduction:
Dermatitis (9%)
Nausea and vomiting (6%)
Other AEs:
Nitrogen retention (1%)
Hematuria (1%)
Drug fever (2%)
Burning eyes (2%)
Conjunctival injection (1%)
Anemia (1%)
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
AEs

AEs

AESignificanceDosePopulation
Anemia 1%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Conjunctival injection 1%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Hematuria 1%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Nitrogen retention 1%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Burning eyes 2%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Drug fever 2%
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Nausea and vomiting 6%
Disc. AE
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Dermatitis 9%
Disc. AE
1 g 6 times / day multiple, oral
Recommended
Dose: 1 g, 6 times / day
Route: oral
Route: multiple
Dose: 1 g, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
unhealthy
n = 100
Health Status: unhealthy
Condition: infection
Population Size: 100
Sources:
https://jamanetwork.com/journals/jama/article-abstract/307661
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChemIDplus
10135894
https://chem.nlm.nih.gov/chemidplus/id/0010135894
PubChem
23675776
https://pubchem.ncbi.nlm.nih.gov/compound/23675776
SureChEMBL
SCHEMBL11626626
https://www.surechembl.org/chemical/SCHEMBL11626626
Wikidata
Q27292401
PubMed

PubMed

TitleDatePubMed
Sensitive spectrophotometric determination of nitrite in human saliva and rain water and of nitrogen dioxide in the atmosphere.
2001 Jan-Feb
Low-level determination of polymorph composition in physical mixtures by near-infrared reflectance spectroscopy.
2001 Mar
Drug release properties of pectinate microspheres prepared by emulsification method.
2002 Aug 21
A new, sensitive, and rapid spectrophotometric method for the determination of sulfa drugs.
2002 Jul-Aug
Face specific surface properties of pharmaceutical crystals.
2002 Jun
3-Aminophenol as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.
2003 Dec
Determination of sulfathiazole in type C medicated swine feed by reversed-phase liquid chromatography with post-column derivatization.
2003 Jul-Aug
Specific polyclonal-based immunoassays for sulfathiazole.
2004 Aug
Serum activity/concentration profiles of a sustained-released formulation of sulphathiazole-trimethoprim (2.5:1) in calves.
2004 Nov 20
Spectroscopic features of radiolytic intermediates induced in gamma irradiated sulfatiazole: an ESR study.
2004 Nov 5
Surface runoff and transport of sulfonamide antibiotics and tracers on manured grassland.
2005 Jul-Aug
Evaluating the biodegradability of sulfamethazine, sulfamethoxazole, sulfathiazole, and trimethoprim at different stages of sewage treatment.
2005 Jun
Controlled release from triple layer, donut-shaped tablets with enteric polymers.
2005 Oct 22
Analysis of Pneumocystis jirovecii DHPS alleles implicated in sulfamethoxazole resistance using an Escherichia coli model system.
2005 Spring
A comparison of morphology and surface energy characteristics of sulfathiazole polymorphs based upon single particle studies.
2006 Jul
Multiwalled carbon nanotubes as sorbent for on-line coupling of solid-phase extraction to high-performance liquid chromatography for simultaneous determination of 10 sulfonamides in eggs and pork.
2006 Sep 15
Exhaustive extraction of sulfonamide antibiotics from aged agricultural soils using pressurized liquid extraction.
2006 Sep 22
Influence of ethanolic extract of Jasminum grandflorum linn flower on wound healing activity in rats.
2007 Apr-Jun
Evaluation of the compaction of sulfathiazole polymorphs.
2007 Aug
Effects of sorbate speciation on sorption of selected sulfonamides in three loamy soils.
2007 Feb 21
Sorption of the veterinary antimicrobial sulfathiazole to organic materials of different origin.
2007 Jan 1
Determination of sulfonamides in milk after precolumn derivatisation by micellar liquid chromatography.
2007 Jun 19
Evaluation of carbon nanotubes as a solid-phase extraction adsorbent for the extraction of cephalosporins antibiotics, sulfonamides and phenolic compounds from aqueous solution.
2007 Jun 26
[Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography].
2007 Mar
Simultaneous determination of different classes of antibiotics in fish and livestock by CE-MS.
2007 Nov
[Simultaneous determination of nine sulfonamide residues in milk using solid phase extraction and high performance liquid chromatography].
2007 Sep
Patents

Patents

08586589
10
JP2009526755A
447

Sample Use Guides

In Vivo Use Guide
Adult: Cream (Sulphathiazole 34.2 mg/g, sulphacetamide 28.6 mg/g, sulphabenzamide 37 mg/g and urea 6.4 mg/g): 5g is applied intra-vaginally bid for 4 to 6 days. Thereafter the dosage may be reduced to one-half or one-quarter.
Route of Administration: Topical
In Vitro Use Guide
25 ug/ml of Sulfathiazole is required for inhibition of in vitro cellulose digestion and volatile fatty acid production by ruminal microorganisms.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:40 UTC 2023
Edited
by admin
on Fri Dec 15 15:10:40 UTC 2023
Record UNII
4KCI0QUF9Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFATHIAZOLE ZINC
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-2-THIAZOLYL-, ZINC SALT
Common Name English
ZINC SULFATHIAZOLE
Common Name English
Code System Code Type Description
FDA UNII
4KCI0QUF9Q
Created by admin on Fri Dec 15 15:10:40 UTC 2023 , Edited by admin on Fri Dec 15 15:10:40 UTC 2023
PRIMARY
PUBCHEM
21571
Created by admin on Fri Dec 15 15:10:40 UTC 2023 , Edited by admin on Fri Dec 15 15:10:40 UTC 2023
PRIMARY
CAS
5434-78-6
Created by admin on Fri Dec 15 15:10:40 UTC 2023 , Edited by admin on Fri Dec 15 15:10:40 UTC 2023
PRIMARY
Related Record Type Details
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Structure of SULFATHIAZOLE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of SULFATHIAZOLE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966